US 7,491,730 B2
Compositions useful as inhibitors of GSK-3
Cornelia J. Forster, Pelham, N.H. (US); Larry C. Park, Waltham, Mass. (US); Marion W. Wannamaker, Bolton, Mass. (US); and Yung-Mae M. Yao, Newton, Mass. (US)
Assigned to Vertex Pharmaceuticals Incorporated, Cambridge, Mass. (US)
Filed on Aug. 01, 2003, as Appl. No. 10/632,340.
Claims priority of provisional application 60/400967, filed on Aug. 02, 2002.
Prior Publication US 2004/0039007 A1, Feb. 26, 2004
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 417/14 (2006.01); A61K 31/4162 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61P 3/10 (2006.01); A61P 9/10 (2006.01); A61P 25/18 (2006.01)
U.S. Cl. 514—275  [514/234.5; 514/252.18; 514/256; 544/328; 544/122; 544/60; 544/295] 15 Claims
 
1. A compound of formula I:

OG Complex Work Unit Drawing
or a pharmaceutically acceptable salt thereof, wherein:
W is nitrogen or CH;
R1 is selected from hydrogen or fluorine; and
Ry is a C1-4 aliphatic group, optionally substituted with N(R2)2 or a 5-6 membered saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:
each R2 is independently selected from hydrogen or a C1-3 aliphatic group optionally substituted with OH, N(R3)2, or a 5-6 membered saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and wherein:
each R3 is independently selected from hydrogen or a C1-3 aliphatic group.